An Economic Comparison of Programmatic and Transactional Development Models

Accelerating drug development is challenging yet critical to maximizing asset value. The faster you can reach key development milestones, the better positioned you are to be efficient with scarce resources and realize the full value of your asset with longer market exclusivity for you or your licensing partner. An important step towards accomplishing this most efficiently may surprise you: adopting the right drug development outsourcing model. Through considered value-based economic analysis, the benefit of a programmatic model over a transactional approach is made tangible and can result in millions of dollars in savings and accelerate development, that collectively positively impact both your asset and company’s financial performance.